Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects.

Legry V, Francque S, Haas JT, Verrijken A, Caron S, Chávez-Talavera O, Vallez E, Vonghia L, Dirinck E, Verhaegen A, Kouach M, Lestavel S, Lefebvre P, Van Gaal L, Tailleux A, Paumelle R, Staels B.

J Clin Endocrinol Metab. 2017 Oct 1;102(10):3783-3794. doi: 10.1210/jc.2017-01397.

PMID:
28938455
2.

Tau deletion promotes brain insulin resistance.

Marciniak E, Leboucher A, Caron E, Ahmed T, Tailleux A, Dumont J, Issad T, Gerhardt E, Pagesy P, Vileno M, Bournonville C, Hamdane M, Bantubungi K, Lancel S, Demeyer D, Eddarkaoui S, Vallez E, Vieau D, Humez S, Faivre E, Grenier-Boley B, Outeiro TF, Staels B, Amouyel P, Balschun D, Buee L, Blum D.

J Exp Med. 2017 Aug 7;214(8):2257-2269. doi: 10.1084/jem.20161731. Epub 2017 Jun 26.

3.

Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance.

Lasalle M, Hoguet V, Hennuyer N, Leroux F, Piveteau C, Belloy L, Lestavel S, Vallez E, Dorchies E, Duplan I, Sevin E, Culot M, Gosselet F, Boulahjar R, Herledan A, Staels B, Deprez B, Tailleux A, Charton J.

J Med Chem. 2017 May 25;60(10):4185-4211. doi: 10.1021/acs.jmedchem.6b01873. Epub 2017 May 5.

PMID:
28414465
4.

Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction.

Catry E, Bindels LB, Tailleux A, Lestavel S, Neyrinck AM, Goossens JF, Lobysheva I, Plovier H, Essaghir A, Demoulin JB, Bouzin C, Pachikian BD, Cani PD, Staels B, Dessy C, Delzenne NM.

Gut. 2018 Feb;67(2):271-283. doi: 10.1136/gutjnl-2016-313316. Epub 2017 Apr 4.

5.

Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease.

Chávez-Talavera O, Tailleux A, Lefebvre P, Staels B.

Gastroenterology. 2017 May;152(7):1679-1694.e3. doi: 10.1053/j.gastro.2017.01.055. Epub 2017 Feb 15. Review.

PMID:
28214524
6.

Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.

Simic B, Mocharla P, Crucet M, Osto E, Kratzer A, Stivala S, Kühnast S, Speer T, Doycheva P, Princen HM, van der Hoorn JW, Jukema JW, Giral H, Tailleux A, Landmesser U, Staels B, Lüscher TF.

Atherosclerosis. 2017 Feb;257:186-194. doi: 10.1016/j.atherosclerosis.2017.01.011. Epub 2017 Jan 16.

PMID:
28152406
7.

Roux-en-Y gastric bypass increases systemic but not portal bile acid concentrations by decreasing hepatic bile acid uptake in minipigs.

Chávez-Talavera O, Baud G, Spinelli V, Daoudi M, Kouach M, Goossens JF, Vallez E, Caiazzo R, Ghunaim M, Hubert T, Lestavel S, Tailleux A, Staels B, Pattou F.

Int J Obes (Lond). 2017 Apr;41(4):664-668. doi: 10.1038/ijo.2017.7. Epub 2017 Jan 17.

PMID:
28093571
8.

Influence of Roux-en-Y gastric bypass on plasma bile acid profiles: a comparative study between rats, pigs and humans.

Spinelli V, Lalloyer F, Baud G, Osto E, Kouach M, Daoudi M, Vallez E, Raverdy V, Goossens JF, Descat A, Doytcheva P, Hubert T, Lutz TA, Lestavel S, Staels B, Pattou F, Tailleux A.

Int J Obes (Lond). 2016 Aug;40(8):1260-7. doi: 10.1038/ijo.2016.46. Epub 2016 Mar 22.

PMID:
27089995
9.

Metabolic effects of bile acid sequestration: impact on cardiovascular risk factors.

Spinelli V, Chávez-Talavera O, Tailleux A, Staels B.

Curr Opin Endocrinol Diabetes Obes. 2016 Apr;23(2):138-44. doi: 10.1097/MED.0000000000000235. Review.

PMID:
26859552
10.

Lipid-lowering drugs prevent neurovascular and cognitive consequences of cardiopulmonary bypass.

Ouk T, Amr G, Azzaoui R, Delassus L, Fossaert E, Tailleux A, Bordet R, Modine T.

Vascul Pharmacol. 2016 May;80:59-66. doi: 10.1016/j.vph.2015.12.005. Epub 2016 Jan 15.

PMID:
26779598
11.

Liver X Receptor Regulates Triglyceride Absorption Through Intestinal Down-regulation of Scavenger Receptor Class B, Type 1.

Briand O, Touche V, Colin S, Brufau G, Davalos A, Schonewille M, Bovenga F, Carrière V, de Boer JF, Dugardin C, Riveau B, Clavey V, Tailleux A, Moschetta A, Lasunción MA, Groen AK, Staels B, Lestavel S.

Gastroenterology. 2016 Mar;150(3):650-8. doi: 10.1053/j.gastro.2015.11.015. Epub 2015 Nov 18.

PMID:
26602218
12.

The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity.

Broeders EP, Nascimento EB, Havekes B, Brans B, Roumans KH, Tailleux A, Schaart G, Kouach M, Charton J, Deprez B, Bouvy ND, Mottaghy F, Staels B, van Marken Lichtenbelt WD, Schrauwen P.

Cell Metab. 2015 Sep 1;22(3):418-26. doi: 10.1016/j.cmet.2015.07.002. Epub 2015 Jul 30.

13.

Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells.

Trabelsi MS, Daoudi M, Prawitt J, Ducastel S, Touche V, Sayin SI, Perino A, Brighton CA, Sebti Y, Kluza J, Briand O, Dehondt H, Vallez E, Dorchies E, Baud G, Spinelli V, Hennuyer N, Caron S, Bantubungi K, Caiazzo R, Reimann F, Marchetti P, Lefebvre P, Bäckhed F, Gribble FM, Schoonjans K, Pattou F, Tailleux A, Staels B, Lestavel S.

Nat Commun. 2015 Jul 2;6:7629. doi: 10.1038/ncomms8629.

14.

Bariatric surgery, lipoprotein metabolism and cardiovascular risk.

Tailleux A, Rouskas K, Pattou F, Staels B.

Curr Opin Lipidol. 2015 Aug;26(4):317-24. doi: 10.1097/MOL.0000000000000197. Review.

PMID:
26103612
15.

Screening strategy to generate cell specific recombination: a case report with the RIP-Cre mice.

Spinelli V, Martin C, Dorchies E, Vallez E, Dehondt H, Trabelsi MS, Tailleux A, Caron S, Staels B.

Transgenic Res. 2015 Oct;24(5):803-12. doi: 10.1007/s11248-015-9889-1. Epub 2015 Jun 20.

PMID:
26091792
16.

Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma.

Guillaumond F, Bidaut G, Ouaissi M, Servais S, Gouirand V, Olivares O, Lac S, Borge L, Roques J, Gayet O, Pinault M, Guimaraes C, Nigri J, Loncle C, Lavaut MN, Garcia S, Tailleux A, Staels B, Calvo E, Tomasini R, Iovanna JL, Vasseur S.

Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2473-8. doi: 10.1073/pnas.1421601112. Epub 2015 Feb 9.

17.

Rapid and body weight-independent improvement of endothelial and high-density lipoprotein function after Roux-en-Y gastric bypass: role of glucagon-like peptide-1.

Osto E, Doytcheva P, Corteville C, Bueter M, Dörig C, Stivala S, Buhmann H, Colin S, Rohrer L, Hasballa R, Tailleux A, Wolfrum C, Tona F, Manz J, Vetter D, Spliethoff K, Vanhoutte PM, Landmesser U, Pattou F, Staels B, Matter CM, Lutz TA, Lüscher TF.

Circulation. 2015 Mar 10;131(10):871-81. doi: 10.1161/CIRCULATIONAHA.114.011791. Epub 2015 Feb 11.

PMID:
25673670
18.

Sox17 regulates liver lipid metabolism and adaptation to fasting.

Rommelaere S, Millet V, Vu Manh TP, Gensollen T, Andreoletti P, Cherkaoui-Malki M, Bourges C, Escalière B, Du X, Xia Y, Imbert J, Beutler B, Kanai Y, Malissen B, Malissen M, Tailleux A, Staels B, Galland F, Naquet P.

PLoS One. 2014 Aug 20;9(8):e104925. doi: 10.1371/journal.pone.0104925. eCollection 2014.

19.

The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice.

Pawlak M, Baugé E, Bourguet W, De Bosscher K, Lalloyer F, Tailleux A, Lebherz C, Lefebvre P, Staels B.

Hepatology. 2014 Nov;60(5):1593-606. doi: 10.1002/hep.27297. Epub 2014 Oct 1.

PMID:
24995693
20.

Cdkn2a/p16Ink4a regulates fasting-induced hepatic gluconeogenesis through the PKA-CREB-PGC1α pathway.

Bantubungi K, Hannou SA, Caron-Houde S, Vallez E, Baron M, Lucas A, Bouchaert E, Paumelle R, Tailleux A, Staels B.

Diabetes. 2014 Oct;63(10):3199-209. doi: 10.2337/db13-1921. Epub 2014 May 1.

21.

The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.

Miranda MX, van Tits LJ, Lohmann C, Arsiwala T, Winnik S, Tailleux A, Stein S, Gomes AP, Suri V, Ellis JL, Lutz TA, Hottiger MO, Sinclair DA, Auwerx J, Schoonjans K, Staels B, Lüscher TF, Matter CM.

Eur Heart J. 2015 Jan 1;36(1):51-9. doi: 10.1093/eurheartj/ehu095. Epub 2014 Mar 6.

22.

Impact of endotoxin challenge in obese pigs.

Duburcq T, Hubert T, Saint-Léger P, Mangalaboyi J, Favory R, Gmyr V, Quintane L, Tailleux A, Staels B, Tournoys A, Pattou F, Jourdain M.

Shock. 2014 Jun;41(6):546-53. doi: 10.1097/SHK.0000000000000158.

PMID:
24569508
23.

Hepatic trans-Golgi action coordinated by the GTPase ARFRP1 is crucial for lipoprotein lipidation and assembly.

Hesse D, Radloff K, Jaschke A, Lagerpusch M, Chung B, Tailleux A, Staels B, Schürmann A.

J Lipid Res. 2014 Jan;55(1):41-52. doi: 10.1194/jlr.M040089. Epub 2013 Nov 1.

24.

Glucose sensing O-GlcNAcylation pathway regulates the nuclear bile acid receptor farnesoid X receptor (FXR).

Berrabah W, Aumercier P, Gheeraert C, Dehondt H, Bouchaert E, Alexandre J, Ploton M, Mazuy C, Caron S, Tailleux A, Eeckhoute J, Lefebvre T, Staels B, Lefebvre P.

Hepatology. 2014 May;59(5):2022-33. doi: 10.1002/hep.26710. Epub 2014 Mar 24.

PMID:
24037988
25.

Long-term prognostic value of preprocedural adiponectin levels in patients undergoing percutaneous coronary intervention.

Delhaye C, Kpogbemabou N, Modine T, Lemesle G, Staels B, Mahmoudi M, Tailleux A, Luc G, Bauters C, Lablanche JM, Sudre A.

Int J Cardiol. 2013 Oct 12;168(5):4921-4. doi: 10.1016/j.ijcard.2013.07.092. Epub 2013 Aug 15. No abstract available.

PMID:
23953633
26.

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt LJ, Baron M, Lucas A, Tailleux A, Hum DW, Ratziu V, Cariou B, Hanf R.

Hepatology. 2013 Dec;58(6):1941-52. doi: 10.1002/hep.26461. Epub 2013 Oct 29.

PMID:
23703580
27.

Endogenous cannabinoid receptor CB1 activation promotes vascular smooth-muscle cell proliferation and neointima formation.

Molica F, Burger F, Thomas A, Staub C, Tailleux A, Staels B, Pelli G, Zimmer A, Cravatt B, Matter CM, Pacher P, Steffens S.

J Lipid Res. 2013 May;54(5):1360-8. doi: 10.1194/jlr.M035147. Epub 2013 Mar 11.

28.

Detrimental effects of diet-induced obesity on τ pathology are independent of insulin resistance in τ transgenic mice.

Leboucher A, Laurent C, Fernandez-Gomez FJ, Burnouf S, Troquier L, Eddarkaoui S, Demeyer D, Caillierez R, Zommer N, Vallez E, Bantubungi K, Breton C, Pigny P, Buée-Scherrer V, Staels B, Hamdane M, Tailleux A, Buée L, Blum D.

Diabetes. 2013 May;62(5):1681-8. doi: 10.2337/db12-0866. Epub 2012 Dec 18.

29.

Normal HDL-apo AI turnover and cholesterol enrichment of HDL subclasses in New Zealand rabbits with partial nephrectomy.

Toledo-Ibelles P, Franco M, Carreón-Torres E, Luc G, Tailleux A, Vargas-Alarcón G, Fragoso JM, Aguilar-Salinas C, Luna-Luna M, Pérez-Méndez O.

Metabolism. 2013 Apr;62(4):492-8. doi: 10.1016/j.metabol.2012.09.010. Epub 2012 Oct 22.

PMID:
23089050
30.

Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production.

Colin S, Briand O, Touche V, Wouters K, Baron M, Pattou F, Hanf R, Tailleux A, Chinetti G, Staels B, Lestavel S.

Eur Heart J. 2013 Aug;34(32):2566-74. doi: 10.1093/eurheartj/ehs227. Epub 2012 Jul 26.

31.

Inhibition of hepatic scavenger receptor-class B type I by RNA interference decreases atherosclerosis in rabbits.

Demetz E, Tancevski I, Duwensee K, Stanzl U, Huber E, Heim C, Handle F, Theurl M, Schroll A, Tailleux A, Dietrich H, Patsch JR, Eller P, Ritsch A.

Atherosclerosis. 2012 Jun;222(2):360-6. doi: 10.1016/j.atherosclerosis.2012.03.012. Epub 2012 Mar 23.

32.

Bone marrow p16INK4a-deficiency does not modulate obesity, glucose homeostasis or atherosclerosis development.

Wouters K, Cudejko C, Gijbels MJ, Fuentes L, Bantubungi K, Vanhoutte J, Dièvart R, Paquet C, Bouchaert E, Hannou SA, Gizard F, Tailleux A, de Winther MP, Staels B, Paumelle R.

PLoS One. 2012;7(3):e32440. doi: 10.1371/journal.pone.0032440. Epub 2012 Mar 5.

33.

Roles of PPARs in NAFLD: potential therapeutic targets.

Tailleux A, Wouters K, Staels B.

Biochim Biophys Acta. 2012 May;1821(5):809-18. doi: 10.1016/j.bbalip.2011.10.016. Epub 2011 Oct 25. Review.

PMID:
22056763
34.

Cell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation?

Baron M, Boulanger CM, Staels B, Tailleux A.

J Cell Mol Med. 2012 Jul;16(7):1365-76. doi: 10.1111/j.1582-4934.2011.01486.x. Review.

35.

p16INK4a deficiency promotes IL-4-induced polarization and inhibits proinflammatory signaling in macrophages.

Cudejko C, Wouters K, Fuentes L, Hannou SA, Paquet C, Bantubungi K, Bouchaert E, Vanhoutte J, Fleury S, Remy P, Tailleux A, Chinetti-Gbaguidi G, Dombrowicz D, Staels B, Paumelle R.

Blood. 2011 Sep 1;118(9):2556-66. doi: 10.1182/blood-2010-10-313106. Epub 2011 Jun 2.

36.

PPARα activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH.

Baron M, Leroyer AS, Majd Z, Lalloyer F, Vallez E, Bantubungi K, Chinetti-Gbaguidi G, Delerive P, Boulanger CM, Staels B, Tailleux A.

Atherosclerosis. 2011 Sep;218(1):69-76. doi: 10.1016/j.atherosclerosis.2011.03.009. Epub 2011 Mar 15.

37.

Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice.

Lalloyer F, Wouters K, Baron M, Caron S, Vallez E, Vanhoutte J, Baugé E, Shiri-Sverdlov R, Hofker M, Staels B, Tailleux A.

Arterioscler Thromb Vasc Biol. 2011 Jul;31(7):1573-9. doi: 10.1161/ATVBAHA.110.220525. Epub 2011 Apr 7.

38.

Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARγ and LXRα pathways.

Chinetti-Gbaguidi G, Baron M, Bouhlel MA, Vanhoutte J, Copin C, Sebti Y, Derudas B, Mayi T, Bories G, Tailleux A, Haulon S, Zawadzki C, Jude B, Staels B.

Circ Res. 2011 Apr 15;108(8):985-95. doi: 10.1161/CIRCRESAHA.110.233775. Epub 2011 Feb 24.

39.

Overview of the Measurement of Lipids and Lipoproteins in Mice.

Tailleux A, Staels B.

Curr Protoc Mouse Biol. 2011 Jun 1;1(2):265-77. doi: 10.1002/9780470942390.mo110001.

PMID:
26069054
40.

Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver.

Lalloyer F, Pedersen TA, Gross B, Lestavel S, Yous S, Vallez E, Gustafsson JA, Mandrup S, Fiévet C, Staels B, Tailleux A.

Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1488-95. doi: 10.1161/ATVBAHA.109.189506. Epub 2009 Jul 10.

41.

Morphologic and electroretinographic phenotype of SR-BI knockout mice after a long-term atherogenic diet.

Provost AC, Vede L, Bigot K, Keller N, Tailleux A, Jaïs JP, Savoldelli M, Ameqrane I, Lacassagne E, Legeais JM, Staels B, Menasche M, Mallat Z, Behar-Cohen F, Abitbol M.

Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3931-42. doi: 10.1167/iovs.08-2527. Epub 2009 May 6.

PMID:
19420333
42.

Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.

Charton J, Deprez-Poulain R, Hennuyer N, Tailleux A, Staels B, Deprez B.

Bioorg Med Chem Lett. 2009 Jan 15;19(2):489-92. doi: 10.1016/j.bmcl.2008.11.040. Epub 2008 Nov 18.

43.

Host glucose metabolism mediates T4 and IL-7 action on Schistosoma mansoni development.

Saule P, Vicogne J, Delacre M, Macia L, Tailleux A, Dissous C, Auriault C, Wolowczuk I.

J Parasitol. 2005 Aug;91(4):737-44.

PMID:
17089737
44.

Influence of high-fat feeding on both naive and antigen-experienced T-cell immune response in DO10.11 mice.

Verwaerde C, Delanoye A, Macia L, Tailleux A, Wolowczuk I.

Scand J Immunol. 2006 Nov;64(5):457-66.

45.

The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia.

Lalloyer F, Fiévet C, Lestavel S, Torpier G, van der Veen J, Touche V, Bultel S, Yous S, Kuipers F, Paumelle R, Fruchart JC, Staels B, Tailleux A.

Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2731-7. Epub 2006 Sep 28.

PMID:
17008586
46.

Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine.

Duval C, Touche V, Tailleux A, Fruchart JC, Fievet C, Clavey V, Staels B, Lestavel S.

Biochem Biophys Res Commun. 2006 Feb 24;340(4):1259-63. Epub 2006 Jan 5.

PMID:
16414355
47.

Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate.

Ribas V, Palomer X, Roglans N, Rotllan N, Fievet C, Tailleux A, Julve J, Laguna JC, Blanco-Vaca F, Escolà-Gil JC.

Biochim Biophys Acta. 2005 Dec 15;1737(2-3):130-7. Epub 2005 Sep 30.

PMID:
16226489
48.

Increased susceptibility of low-density lipoprotein to ex vivo oxidation in mice transgenic for human apolipoprotein B treated with 1 melatonin-related compound is not associated with atherosclerosis progression.

Tailleux A, Gozzo A, Torpier G, Martin-Nizard F, Bonnefont-Rousselot D, Lemdani M, Furman C, Foricher R, Chevé G, Yous S, Micard F, Bordet R, Gardes-Albert M, Lesieur D, Teissier E, Fruchart JC, Fiévet C, Duriez P.

J Cardiovasc Pharmacol. 2005 Sep;46(3):241-9.

PMID:
16116326
49.

PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.

Hennuyer N, Tailleux A, Torpier G, Mezdour H, Fruchart JC, Staels B, Fiévet C.

Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1897-902. Epub 2005 Jun 30.

PMID:
15994444
50.

Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis.

Tailleux A, Torpier G, Mezdour H, Fruchart JC, Staels B, Fiévet C.

Trends Pharmacol Sci. 2003 Oct;24(10):530-4. Review. No abstract available.

PMID:
14559405

Supplemental Content

Loading ...
Support Center